Philipp Hohn

St. Josef Hospital
Bochum, NW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

Biochemical Early Detection of Postoperative Pancreatic Fistula.

Biochemical Early Detection of Postoperative Pancreatic Fistula.

Journal: Visceral medicine

Published: September 25, 2024

Use of Histomorphological Features for the Prediction of Grade C Fistula after Whipple Procedure: A Difficult Task.

Use of Histomorphological Features for the Prediction of Grade C Fistula after Whipple Procedure: A Difficult Task.

Journal: Visceral medicine

Published: September 13, 2024

Maintenance Therapy for Pancreatic Cancer, a New Approach Based on the Synergy between the Novel Agent GP-2250 (Misetionamide) and Gemcitabine.

Maintenance Therapy for Pancreatic Cancer, a New Approach Based on the Synergy between the Novel Agent GP-2250 (Misetionamide) and Gemcitabine.

Journal: Cancers

Published: July 10, 2024

Differential miRNA and Protein Expression Reveals miR-1285, Its Targets TGM2 and CDH-1, as Well as CD166 and S100A13 as Potential New Biomarkers in Patients with Diabetes Mellitus and Pancreatic Adenocarcinoma.

Differential miRNA and Protein Expression Reveals miR-1285, Its Targets TGM2 and CDH-1, as Well as CD166 and S100A13 as Potential New Biomarkers in Patients with Diabetes Mellitus and Pancreatic Adenocarcinoma.

Journal: Cancers

Published: June 21, 2024

Next-generation microbiological testing in intraabdominal infections with PCR technology.

Next-generation microbiological testing in intraabdominal infections with PCR technology.

Journal: Langenbeck's archives of surgery

Published: November 13, 2023

Oxathiazinane derivatives display both antineoplastic and antibacterial activity: a structure activity study.

Oxathiazinane derivatives display both antineoplastic and antibacterial activity: a structure activity study.

Journal: Journal of cancer research and clinical oncology

Published: February 17, 2023

GP-2250, a novel anticancer agent, inhibits the energy metabolism, activates AMP-Kinase and impairs the NF-kB pathway in pancreatic cancer cells.

GP-2250, a novel anticancer agent, inhibits the energy metabolism, activates AMP-Kinase and impairs the NF-kB pathway in pancreatic cancer cells.

Journal: Journal of cellular and molecular medicine

Published: December 14, 2022

Unusual paraneoplastic syndromes in pancreatic cancer: a case report of Lambert-Eaton myasthenic syndrome (LEMS) associated with intraductal papillary mucinous cancer of the pancreas.

Unusual paraneoplastic syndromes in pancreatic cancer: a case report of Lambert-Eaton myasthenic syndrome (LEMS) associated with intraductal papillary mucinous cancer of the pancreas.

Journal: AME case reports

Published: December 10, 2022

Applicability of the surgical risk calculator by the American College of Surgeons in the setting of German patients undergoing complete pancreatectomy: multicentre study using data from the StuDoQ|Pancreas registry.

Applicability of the surgical risk calculator by the American College of Surgeons in the setting of German patients undergoing complete pancreatectomy: multicentre study using data from the StuDoQ|Pancreas registry.

Journal: BJS open

Published: August 21, 2022

Risk Factor Identification for Delayed Gastric Emptying after Distal Pancreatectomy-An Evaluation of 1688 Patients Based on the German StuDoQ|Pancreas Registry.

Risk Factor Identification for Delayed Gastric Emptying after Distal Pancreatectomy-An Evaluation of 1688 Patients Based on the German StuDoQ|Pancreas Registry.

Journal: Journal of clinical medicine

Published: July 27, 2022

Substance GP-2250 as a New Therapeutic Agent for Malignant Peritoneal Mesothelioma-A 3-D In Vitro Study.

Substance GP-2250 as a New Therapeutic Agent for Malignant Peritoneal Mesothelioma-A 3-D In Vitro Study.

Journal: International journal of molecular sciences

Published: May 26, 2022

New Therapy Options for Neuroendocrine Carcinoma of the Pancreas-The Emergent Substance GP-2250 and Gemcitabine Prove to Be Highly Effective without the Development of Secondary Resistances In Vitro and In Vivo.

New Therapy Options for Neuroendocrine Carcinoma of the Pancreas-The Emergent Substance GP-2250 and Gemcitabine Prove to Be Highly Effective without the Development of Secondary Resistances In Vitro and In Vivo.

Journal: Cancers

Published: April 26, 2022

Showing 1-12 of 26

Last Updated: 09/26/2026